Community Programs for Clinical Research on AIDS: Difference between revisions

Revision as of 22:41, 25 November 2018

Revision as of 15:43, 20 May 2019

Line 8:

The CPCRA was one of four networks that NIH was using to conduct clinical trials that were looking to understand possible therapies for people with HIV infection.<ref>{{cite press release |url=https://aidsinfo.nih.gov/news/123/niaid-research-on-aids |title=NIAID Research on AIDS |publisher=aidsinfo.nih.gov |date= 1 January 1995 |accessdate=22 April 2016}}</ref> Th CPCRA network was community-based with access to diverse populations across the spectrum of HIV diseases..."<ref>[http://cpcra.s-3.com/]</ref>

The overall objective of the CPCRA is to design studies of sufficient size and duration of follow up to evaluate the long-term benefits and [[unintended consequence]]s of various treatment strategies using available agents to assess long-term immunologic, virologicvirology and clinical outcomes. CPCRA trials are designed with nested substudiessub-studies aimed at understanding the pathogenesis of HIV infection and the public health implications of its treatment.<ref>{{cite web|url=http://www.niaid.nih.gov/DAIDs/pdatguide/cpcra.htm |title=Archived copy |accessdate=April 17, 2007 |deadurl=yes |archiveurl=https://web.archive.org/web/20070703233645/http://www.niaid.nih.gov/daids/PDATguide/cpcra.htm |archivedate=July 3, 2007 }}</ref>

By 2001, CPCRA had 4,244 people participating in their studies, with trials underway in 17 cities.<ref>{{cite press release |url=https://aidsinfo.nih.gov/news/41/hiv-infection-in-minority-populations |title=HIV Infections in Minority Populations |publisher=aidsinfo.nih.gov |date =1 June 2002 |accessdate=22 April 2016}}</ref>

The [[International Network for Strategic Initiatives in Global HIV Trials]] (INSIGHT) biorepositorybio-repository system has its roots in the CPCRA.<ref>{{cite journal |pmc=3039520 |title=Designing and managing a flexible and dynamic biorepository system: a 15 year perspective from the CPCRA, ESPRIT, and INSIGHT clinical trial networks |first1=Katherine |last1=Huppler Hullsiek |first2=Michelle |last2=George |first3=Shawn K. |last3=Brown |journal=Curr Opin HIV AIDS |date=November 2010 |volume=5 |issue=6 |pages=538–544 |doi=10.1097/COH.0b013e32833f2058 |pmid=20978398}}</ref>

==Research==

An antiretroviral medication self-reporting questionnaire was developed by the programme.<ref>{{cite journal |url=http://cid.oxfordjournals.org/content/34/8/1115.full |title=The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials |first1=Sharon |last1=Mannheimer |first2=Gerald |last2=Friedland |first3=John |last3=Matts |first4=Carroll |last4=Child |first5=Margaret |last5=Chesney |journal=Clinical Infectious Diseases |year=2002 |volume=34 |issue=8 |pages=1115–21 |doi=10.1086/339074 |pmid=11915001}}</ref>

The programme organised the 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial: a large, long-term, randomizedrandomised, prospective comparison of three different antiretroviral strategies in [[highly active antiretroviral therapy]]-naïve, HIV-1-infected persons.<ref>{{cite journal |url=http://www.sciencedirect.com/science/article/pii/S0197245601001118 |title=The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial |last1=MacArthur |first1=RD |last2=Chen |first2=L |last3=Mayers |first3=DL |last4=Besch |first4=CL |last5=Novak |first5=R |last6=van den Berg-Wolf |first6=M |last7=Yurik |first7=T |last8=Peng |first8=G |last9=Schmetter |first9=B |last10=Brizz |first10=B |last11=Abrams |first11=D |journal=Control Clin Trials |date=April 2001 |volume=22 |issue=2 |pages=176–90 |doi=10.1016/S0197-2456(01)00111-8|pmid=11306155 }}</ref>

==References==